Growth characteristics of myelodysplastic CD34+ cells.
Myelodysplastic syndromes (MDS) are a heterogeneous group of disorders of hematopoiesis entailing hyperproliferative and ineffective hematopoiesis associated with morphologic evidence of marrow cell dysplasia resulting in refractory cytopenia(s), and an increased risk of transformation into acute myeloblastic leukemia (AML). The administration of colony-stimulating factor(s) (CSFs) to patients with MDS increased blood neutrophil concentrations, in most patients, and it was anticipated to be of benefit to prevent infections. The progression to AML while being treated with CSFs has come under close scrutiny. In vitro studies are expected to produce more pertinent criteria for selection of patients who are likely to benefit, as well as the overall benefits of various therapies. For this purpose, in vitro colony assays are an excellent approach for investigation of the biologic characteristics of MDS progenitor cells. The stem cell phenotype CD34 is the one of the best markers of progenitor cells, and can be used for the purification of these cells to unify levels of maturation; a direct comparison of proliferative and differentiative capacity of MDS progenitor cells with normal CD34+ cells can thus be made. The properties of MDS CD34+ cells are described here in association with proliferation and differentiation, with special emphasis on the role of stem cell factor (a ligand for c-kit) in leukemic type growth of MDS CD34+ cells.
Sawada
K
K
Department of Internal Medicine II, Hokkaido University School of Medicine, Sapporo, Japan. ksawada@med.hokudai.ac.jp
D018952:Antigens, CD34 / Q000097:blood*; D002455:Cell Division / Q000276:immunology; D003114:Colony-Forming Units Assay; D016207:Cytokines / Q000502:physiology; D006801:Humans; D007951:Leukemia, Myeloid / Q000276:immunology; D009190:Myelodysplastic Syndromes / Q000276:immunology* / Q000473:pathology; D013234:Stem Cells / Q000276:immunology
D018952:Antigens, CD34; D016207:Cytokines